PMID- 17875951
OWN - NLM
STAT- MEDLINE
DCOM- 20071025
LR  - 20131121
IS  - 1074-2484 (Print)
IS  - 1074-2484 (Linking)
VI  - 12
IP  - 3
DP  - 2007 Sep
TI  - Intermittent outpatient nesiritide infusion reduces hospital admissions in 
      patients with advanced heart failure.
PG  - 232-6
AB  - Recombinant B-type natriuretic peptide (BNP) is a therapeutic modality in 
      patients with decompensated congestive heart failure. Retrospectively tested are 
      the effects of intermittent outpatient nesiritide infusion on symptoms, hospital 
      readmission rates, endogenous BNP, and renal function in patients with advanced 
      heart failure. Twenty-four patients in heart failure in New York Heart 
      Association (NYHA) classes III-IV received a 6- to 8-hour intermittent nesiritide 
      outpatient infusion (0.01 mcg/kg/min continuously intravenously) once weekly for 
      a total duration of 3 months in addition to standard medical therapy. Data were 
      analyzed retrospectively to compare hospital readmission rates, endogenous BNP 
      levels, blood urea nitrogen, and creatinine levels 1 year before and up to 12 
      months after starting treatment. All patients tolerated nesiritide infusions well 
      with no significant adverse events. At the end of the observation period, NYHA 
      classes had improved 1 class in 16 patients and 2 classes in 4 patients and 
      remained unchanged in 4 patients. There was a significant reduction in hospital 
      readmissions within 1 year with nesiritide treatment compared with the year 
      before (0.94 +/- 0.8 vs 3.6 +/- 2.2, P < .005). No significant changes were seen 
      regarding endogenous BNP levels (1002 +/- 870 vs 1092 +/- 978 pg/mL, P = .95), 
      blood urea nitrogen levels (45 +/- 28 vs 45 +/- 26 mg/dL, P = .96), and a 
      tendency of slightly elevated creatinine levels that did not differ significantly 
      compared with prior levels (1.76 +/- 0.85 vs 1.1 +/- 0.56 mg/dL, P = .5). 
      Intermittent outpatient nesiritide treatment resulted in improved symptoms and 
      reduced hospital readmission rates without a significant decline in renal 
      function in patients with advanced heart failure but did not alter endogenous BNP 
      levels.
FAU - Schwarz, Ernst R
AU  - Schwarz ER
AD  - Division of Cardiology, Cedars Sinai Medical Center and University of California 
      Los Angeles, Los Angeles, California 90048, USA. ernst.schwarz@cshs.org
FAU - Najam, Sabeen
AU  - Najam S
FAU - Akel, Rami
AU  - Akel R
FAU - Sulimanjee, Nasir
AU  - Sulimanjee N
FAU - Bionat, Susan
AU  - Bionat S
FAU - Rosanio, Salvatore
AU  - Rosanio S
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Cardiovasc Pharmacol Ther
JT  - Journal of cardiovascular pharmacology and therapeutics
JID - 9602617
RN  - 0 (Natriuretic Agents)
RN  - 0 (Recombinant Proteins)
RN  - 114471-18-0 (Natriuretic Peptide, Brain)
RN  - AYI8EX34EU (Creatinine)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Ambulatory Care
MH  - Blood Urea Nitrogen
MH  - Creatinine/blood
MH  - Drug Therapy, Combination
MH  - Female
MH  - Heart Failure/*drug therapy
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Natriuretic Agents/adverse effects/*therapeutic use
MH  - Natriuretic Peptide, Brain/adverse effects/blood/*therapeutic use
MH  - Patient Readmission
MH  - Recombinant Proteins/adverse effects/therapeutic use
MH  - Retrospective Studies
EDAT- 2007/09/19 09:00
MHDA- 2007/10/27 09:00
CRDT- 2007/09/19 09:00
PHST- 2007/09/19 09:00 [pubmed]
PHST- 2007/10/27 09:00 [medline]
PHST- 2007/09/19 09:00 [entrez]
AID - 12/3/232 [pii]
AID - 10.1177/1074248407303657 [doi]
PST - ppublish
SO  - J Cardiovasc Pharmacol Ther. 2007 Sep;12(3):232-6. doi: 10.1177/1074248407303657.